A Phase 1 Open Label, Single Dose, Parallel-Group Study to Determine the Pharmacokinetics of Pacritinib in Patients With Impaired Hepatic Function in Comparison With Healthy Subjects
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Pacritinib (Primary)
- Indications Myelofibrosis
- Focus Pharmacokinetics
- Sponsors CTI BioPharma
- 11 May 2016 New trial record